Ryvu Therapeutics to Present Phase II Updates on RVU120 at Investor Event on December 12, 2024
2024-12-10 · Ryvu Therapeutics SA · original ryvu.com ↗
Krakow, Poland – December 10, 2024—Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focused on novel oncology therapies, will host a live investor event on December 12, 2024, to present the latest updates on RVU120, its fully owned, first-in-class dual CDK8/19 inhibitor. The event will feature insights from Ryvu’s leadership team: Pawel Przewiezlikowski, Chief Executive Officer Hendrik Nogai, Chief Medical Officer Kamil Sitarz, Chief Operating Officer Event Details: Date: December 12, 2024 Time: 10:00 CET Location: online – join the live stream This event allows investors and stakeholders to gain deeper insights into RVU120’s clinical progress and the strategic direction behind its development. We encourage all interested parties to participate in this live conference to stay informed about the latest developments in our oncology pipeline. For more information about Ryvu Therapeutics and our ongoing research, please visit our website.
The release as fetched from its publisher. ryvu.com ↗